Showing results (301-310 of 375) with videos related to
Sort By:
Pageof 38
Journal of Clinical Medicine|August 12, 2018
Inclusion and Exclusion Criteria of Clinical Trials for InsomniaHendrikje Huls, Smedra Abdulahad, Marlou Mackus, et al.Journal of Synchrotron Radiation|July 6, 2019
Diffraction properties of a strongly bent diamond crystal used as a dispersive spectrometer for XFEL pulsesLiubov Samoylova, Ulrike Boesenberg, Aleksandr Chumakov, et al.Journal of Sleep Research|August 25, 2025
Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of NarcolepsyLuis E Ortiz, Anne Marie Morse, Michael J Thorpy, et al.Clinical Therapeutics|April 2, 2013
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adultsDavid J Greenblatt, Jerold S Harmatz, Thomas Roth, et al.CNS Drugs|April 5, 2022
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON TrialThomas Roth, Yves Dauvilliers, Michael J Thorpy, et al.Nature and Science of Sleep|July 27, 2018
Hyperarousal and sleep reactivity in insomnia: current insightsDavid A Kalmbach, Andrea S Cuamatzi-Castelan, Christine V Tonnu, et al.Sleep Advances : a Journal of the Sleep Research Society|May 16, 2023
Validation of Somno-Art Software, a novel approach of sleep staging, compared with polysomnography in disturbed sleep profilesLaurie Thiesse, Luc Staner, Patrice Bourgin, et al.Journal of Child and Adolescent Psychopharmacology|April 12, 2011
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorderScott H Kollins, Frank A López, Bradley D Vince, et al.The Lancet. Neurology|January 22, 2022
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsEmmanuel Mignot, David Mayleben, Ingo Fietze, et al.Sleep|February 26, 2009
A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndromeClete A Kushida, Arthur S Walters, Philip Becker, et al.Pageof 38